271 related articles for article (PubMed ID: 35880350)
21. Whole-body MR imaging in detecting phosphaturic mesenchymal tumor (PMT) in tumor-induced hypophosphatemic osteomalacia.
Nakanishi K; Sakai M; Tanaka H; Tsuboi H; Hashimoto J; Hashimoto N; Tomiyama N
Magn Reson Med Sci; 2013 Mar; 12(1):47-52. PubMed ID: 23474956
[TBL] [Abstract][Full Text] [Related]
22. Tumor-induced osteomalacia: a case report.
Romualdo-Silva DD; Silva BC; Caetano CV; Tibúrcio AM; Nunes MB; Chagas SA; Polito ET; Ferreira AR; Purisch S
Arq Bras Endocrinol Metabol; 2009 Apr; 53(3):378-82. PubMed ID: 19578602
[TBL] [Abstract][Full Text] [Related]
23. Tumour-induced osteomalacia.
Minisola S; Peacock M; Fukumoto S; Cipriani C; Pepe J; Tella SH; Collins MT
Nat Rev Dis Primers; 2017 Jul; 3():17044. PubMed ID: 28703220
[TBL] [Abstract][Full Text] [Related]
24. Varied presentation of sinonasal phosphaturic mesenchymal tumour: report of a case series with follow-up.
Kurien R; Rupa V; Thomas M
Eur Arch Otorhinolaryngol; 2019 Jun; 276(6):1677-1684. PubMed ID: 30879192
[TBL] [Abstract][Full Text] [Related]
25. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss.
Ghorbani-Aghbolaghi A; Darrow MA; Wang T
Autops Case Rep; 2017; 7(3):32-37. PubMed ID: 29043208
[TBL] [Abstract][Full Text] [Related]
26. Tumor-induced osteomalacia: An overview.
Jadhav SS; Shah R; Patil V
Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101834. PubMed ID: 37935612
[TBL] [Abstract][Full Text] [Related]
27. Phosphaturic mesenchymal tumor of the brain without tumor-induced osteomalacia in an 8-year-old girl: case report.
Ellis MB; Gridley D; Lal S; Nair GR; Feiz-Erfan I
J Neurosurg Pediatr; 2016 May; 17(5):573-7. PubMed ID: 26722864
[TBL] [Abstract][Full Text] [Related]
28. Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia.
Higley M; Beckett B; Schmahmann S; Dacey E; Foss E
Skeletal Radiol; 2015 Dec; 44(12):1825-31. PubMed ID: 26341245
[TBL] [Abstract][Full Text] [Related]
29. Sinonasal hemangiopericytoma caused hypophosphatemic osteomalacia: A case report.
Li J; Huang Y; Yang F; Zhang Q; Chen D; Wang Q
Medicine (Baltimore); 2018 Dec; 97(52):e13849. PubMed ID: 30593185
[TBL] [Abstract][Full Text] [Related]
30. Tumor-Induced Osteomalacia Caused by a Phosphaturic Mesenchymal Tumor of the Sole Presenting as a Crippling Illness in a Postmenopausal Woman.
Fang X; Zhang W; Yu Z; Liu H; Xiong Y; Luo Y; Song L; Li J; Duan H
J Foot Ankle Surg; 2020; 59(5):1113-1117. PubMed ID: 32622675
[TBL] [Abstract][Full Text] [Related]
31. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature.
Jiang Y; Xia WB; Xing XP; Silva BC; Li M; Wang O; Zhang HB; Li F; Jing HL; Zhong DR; Jin J; Gao P; Zhou L; Qi F; Yu W; Bilezikian JP; Meng XW
J Bone Miner Res; 2012 Sep; 27(9):1967-75. PubMed ID: 22532501
[TBL] [Abstract][Full Text] [Related]
32. Phosphaturic mesenchymal tumor: A chondromyxoid fibroma-like type.
Koga K; Iwasaki H; Nabeshima K
J Dermatol; 2023 Nov; 50(11):1484-1487. PubMed ID: 37350024
[TBL] [Abstract][Full Text] [Related]
33. [Tumor-induced osteomalacia caused by an FGF23-secreting myopericytoma : Case report and literature review].
Muro Bushart N; Tharun L; Oheim R; Paech A; Kiene J
Orthopade; 2020 Jan; 49(1):1-9. PubMed ID: 30937490
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant.
Shiba E; Matsuyama A; Shibuya R; Yabuki K; Harada H; Nakamoto M; Kasai T; Hisaoka M
Diagn Pathol; 2016 Mar; 11():26. PubMed ID: 26956379
[TBL] [Abstract][Full Text] [Related]
35. Tumor-induced osteomalacia: experience from a South American academic center.
González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
[TBL] [Abstract][Full Text] [Related]
36. A Phosphaturic Mesenchymal Tumor Presenting as Reversible Metabolic Myopathy.
Abdulla M
Saudi J Kidney Dis Transpl; 2023 Nov; 34(6):666-670. PubMed ID: 38725216
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.
Leaf DE; Pereira RC; Bazari H; Jüppner H
J Clin Endocrinol Metab; 2013 Mar; 98(3):887-91. PubMed ID: 23393166
[TBL] [Abstract][Full Text] [Related]
38. Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia.
Nelson AE; Bligh RC; Mirams M; Gill A; Au A; Clarkson A; Jüppner H; Ruff S; Stalley P; Scolyer RA; Robinson BG; Mason RS; Bligh PC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4088-94. PubMed ID: 12970268
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
40. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
